Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Profit After Tax (2021 - 2025)

Historic Profit After Tax for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$34.4 million.

  • Amylyx Pharmaceuticals' Profit After Tax rose 5270.41% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 4246.57%. This contributed to the annual value of -$301.7 million for FY2024, which is 71241.5% down from last year.
  • Amylyx Pharmaceuticals' Profit After Tax amounted to -$34.4 million in Q3 2025, which was up 5270.41% from -$41.4 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Profit After Tax's 5-year high stood at $22.1 million during Q2 2023, with a 5-year trough of -$118.8 million in Q1 2024.
  • In the last 5 years, Amylyx Pharmaceuticals' Profit After Tax had a median value of -$35.9 million in 2025 and averaged -$34.2 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Profit After Tax soared by 14082.71% in 2023 and then tumbled by 765200.25% in 2024.
  • Amylyx Pharmaceuticals' Profit After Tax (Quarter) stood at -$28.3 million in 2021, then tumbled by 50.66% to -$42.7 million in 2022, then surged by 111.08% to $4.7 million in 2023, then crashed by 893.62% to -$37.5 million in 2024, then grew by 8.42% to -$34.4 million in 2025.
  • Its Profit After Tax was -$34.4 million in Q3 2025, compared to -$41.4 million in Q2 2025 and -$35.9 million in Q1 2025.